格隆汇1月20日|方正证券研报指出,君实生物-U(688180.SH)预计2024年收入19.49亿元,同比增长29.71%,归母净利润-12.92亿元,同比亏损减少43.42%。公司营收超预期,亏损大幅缩窄。营收端增加得益于商业化团队销售效率提升,预计核心产品特瑞普利单抗国内销售大幅增加,目前特瑞普利已获批十项适应症,且全部纳入医保。预计特瑞普利将于2025-2026年在全球开启放量节奏。此外,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.